Gregory Friberg is a notable inventor based in Westlake Village, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic methods. With a total of 2 patents, Friberg's work focuses on advancing medical treatments for tumor diseases.

Latest Patents

Friberg's latest patents include groundbreaking methods and compositions for treating tumor diseases. The first patent provides methods for treating tumors in human subjects by inhibiting IGF-1 receptor signaling. This invention also includes methods for determining a tumor's likelihood of responding to such treatment, along with compositions for practicing these methods. Notably, it features fully human, humanized, or chimeric anti-IGF-1R antibodies that bind to human IGF-1R, as well as related fragments and derivatives. The second patent involves the use of AMG 900, a small molecule pan aurora kinase inhibitor, for treating various types of cancer, including solid tumors and hematologically derived tumors. This invention outlines pharmaceutical compositions, dosage ranges, and treatment regimens for administering AMG 900 effectively.

Career Highlights

Friberg's career is marked by his dedication to cancer research and his role at Amgen Inc., a leading biotechnology company. His work has contributed to the development of innovative therapies that aim to improve patient outcomes in oncology.

Collaborations

Throughout his career, Friberg has collaborated with esteemed colleagues, including Marc Payton and Pedro J Beltran. These partnerships have fostered a collaborative environment that enhances the research and development of cancer treatments.

Conclusion

Gregory Friberg's contributions to cancer treatment through his patents and work at Amgen Inc. highlight his commitment to advancing medical science. His innovative approaches continue to pave the way for new therapeutic options in oncology.

This text is generated by artificial intelligence and may not be accurate.